VYLEESI Drug Patent Profile
✉ Email this page to a colleague
When do Vyleesi patents expire, and when can generic versions of Vyleesi launch?
Vyleesi is a drug marketed by Cosette and is included in one NDA. There are four patents protecting this drug.
The generic ingredient in VYLEESI is bremelanotide acetate. Two suppliers are listed for this compound. Additional details are available on the bremelanotide acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Vyleesi
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VYLEESI?
- What are the global sales for VYLEESI?
- What is Average Wholesale Price for VYLEESI?
Summary for VYLEESI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for VYLEESI |
| What excipients (inactive ingredients) are in VYLEESI? | VYLEESI excipients list |
| DailyMed Link: | VYLEESI at DailyMed |
US Patents and Regulatory Information for VYLEESI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cosette | VYLEESI (AUTOINJECTOR) | bremelanotide acetate | SOLUTION;SUBCUTANEOUS | 210557-001 | Jun 21, 2019 | RX | Yes | Yes | 9,352,013 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Cosette | VYLEESI (AUTOINJECTOR) | bremelanotide acetate | SOLUTION;SUBCUTANEOUS | 210557-001 | Jun 21, 2019 | RX | Yes | Yes | 10,286,034 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Cosette | VYLEESI (AUTOINJECTOR) | bremelanotide acetate | SOLUTION;SUBCUTANEOUS | 210557-001 | Jun 21, 2019 | RX | Yes | Yes | 11,590,209 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |


